Two-Year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

Movement Disorders

Volumn 29, Issue 10, 2014, Pages 1273-1280

  Borgohain, Rupam ^a   Szasz, Jozsef ^b   Stanzione, Paolo ^c   Meshram, Chandrashekhar ^d   Bhatt, Mohit H ^e   Chirilineau, Dana ^f   Stocchi, Fabrizio ^g   Lucini, Valentina ^h   Giuliani, Rodolfo ^h   Forrest, Emma ^h   Rice, Patricia ⁱ   Anand, Ravi ^j   Illiyas Sahadulla, M ^k   Kardan, U ^k   Keshava, B S ^k   Kishore, A ^k   Kothari, S S ^k   Krishna Murthy, J M ^k   Kumar, S ^k   Kumar Pal, P ^k   Mehta, N ^k   Prabhakar, S ^k   Prabhakar, S Kr ^k   Pradhan, S ^k   Roy, A K ^k   Sankhla, C ^k   Sethi, P K ^k   Shah, A B ^k   Shankar, N ^k   Shukla, R ^k   Sowani, A ^k   Srinivasa, R ^k   Varma, M ^k   Vasudevan, D ^k   Vavilikolanu Sreenivas, P ^k   Velmurugendran, C U ^k   Vijayan, K ^k   Bajenaru, O ^k   Bulboaca, A ^k   Campeanu, A ^k   Chirileanu, D ^k   Muresanu, D ^k   Panea, C ^k   Popescu, C ^k   Simu, M ^k   Szasz, J ^k   Ticmeanu, M ^k   Avarello, T ^k   Bonuccelli, U ^k   Eleopra, R ^k   Onofrj, M ^k   Quatrale, R ^k   Stanzione, P ^k   Stocchi, F ^k   more..

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Brain and Mind Institute   (India)

^e Kokilaben Dhirubhai Ambani Hospital   (India)

^f VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g IRCCS SAN RAFFAELE PISANA   (Italy)

^h Newron Pharmaceuticals SpA   (Italy)

ⁱ Premier Research   (United States)

^j APC AG   (Switzerland)

^k NONE   (Italy)

more..

Author keywords

Addon; Dopamine; Levodopa; Motor function; Parkinson's disease; Safinamide

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PLACEBO; SAFINAMIDE; ALANINE; ANTIPARKINSON AGENT; BENZYLAMINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CATARACT; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSKINESIA RATING SCALE; EVALUATION STUDY; FALLING; FATIGUE; FEMALE; FEVER; HALLUCINATION; HUMAN; HYPERTENSION; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; ALANINE; ANTIPARKINSON AGENTS; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84908473443     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25961     Document Type: Article

References (17)

1. LeWitt PA. Levodopa therapeutics for Parkinson's disease: new developments. Parkinsonism Relat Disord 2009;15(Suppl 1):S31-34.
2. Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009; 62:1-8.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, doubleblind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012;27:106-112.
5. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63: 746-748.
6. Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014;29:229-237.
7. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(7 Suppl 2):S18-S23.
8. Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: beyond MAO-B inhibition. Parkinsonism Relat Disord 2007;13(Suppl 2): S99.
9. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Current Opinion in Investigational Drugs 2007;8:570-579.
10. Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem 1998;41:579-590.
11. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(7 Suppl 2):S24-29.
12. Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003;5: 139-146.
13. Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013;19:508-514.
14. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
15. Barone P, Fernandez H, Ferreira JJ, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study) [Abstract]. 65th AAN Annual Meeting, American Academy of Neurology, 16-23 March 2013, San Diego, California, USA. Neurology 2013;80(Meeting Abstracts 1):P01.061.
16. Schapira AH, Fox S, Hauser RA, et al. Safinamide add on to Ldopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson's Disease (PD) and Motor fluctuations (SETTLE) [Abstract]. 65th AAN Annual Meeting, American Academy of Neurology, 16-23 March 2013, San Diego, California, USA. Neurology 2013;80(Meeting Abstracts 1):P01.062.
17. Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011;26:587-598.